ALZAMEND NEURO, INC. Net Income (Loss) Available to Common Stockholders, Diluted
ALZAMEND NEURO, INC. (ALZN) reported Net Income (Loss) Available to Common Stockholders, Diluted of $1.00 million for the 3-month period ending 2025-01-31, per its 10-Q filed 2025-03-10.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2025-03-10
- ALZAMEND NEURO, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-01-31 was $1.00M.
- ALZAMEND NEURO, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2024-10-31 was $1.40M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month |
|---|---|---|---|
| 2025-01-31 | $1.00M 10-Q · filed 2025-03-10 | $2.40M derived: sum of 2 quarters · filed 2025-03-10 | $3.40M 10-Q · filed 2025-03-10 |
| 2024-10-31 | $1.40M 10-Q · filed 2024-12-11 | $2.40M 10-Q · filed 2024-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |